First human test of new cancer imaging agent begins
NCT ID NCT05799274
Summary
This early-stage study aims to understand the safety and imaging properties of an experimental radioactive tracer called RAD301. The research involves 9 participants, including both healthy volunteers and people with specific cancers like pancreatic, lung, or ovarian cancer. Participants receive a single injection of RAD301 and undergo several PET scans to see where the tracer goes in the body and measure radiation exposure to organs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10461, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
United Theranostics
RECRUITINGPrinceton, New Jersey, 08540, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.